Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy.

ABSTRACT:

Background

In Italy HPV vaccination with the quadrivalent vaccine (Gardasil^®) is offered actively and free of charge to girls aged 12 since 2007. A nine-valent vaccine (Gardasil 9^®) received the European market authorization in 2015 to protect, with only 2 doses, against around 90% of all HPV positive cancers, over 80% of high-grade precancerous lesions and 90% of genital warts caused by HPV types 6/11.

Methods

A dynamic transmission model simulating the natural history of HPV-infections was calibrated to the Italian setting and used to estimate costs and QALYs associated with vaccination strategies. The analyses compared two strategies with the nine-valent vaccine (cervical cancer screening and vaccination in girls only or vaccination in boys and girls

SUBMITTER: Mennini FS 

PROVIDER: S-EPMC5504713 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature